295 related articles for article (PubMed ID: 35387480)
1. 2021 Jeffrey M. Hoeg Award Lecture: Defining the Role of Efferocytosis in Cardiovascular Disease: A Focus on the CD47 (Cluster of Differentiation 47) Axis.
Jarr KU; Kojima Y; Weissman IL; Leeper NJ
Arterioscler Thromb Vasc Biol; 2022 Jun; 42(6):e145-e154. PubMed ID: 35387480
[TBL] [Abstract][Full Text] [Related]
2. Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade.
Wang Y; Nanda V; Direnzo D; Ye J; Xiao S; Kojima Y; Howe KL; Jarr KU; Flores AM; Tsantilas P; Tsao N; Rao A; Newman AAC; Eberhard AV; Priest JR; Ruusalepp A; Pasterkamp G; Maegdefessel L; Miller CL; Lind L; Koplev S; Björkegren JLM; Owens GK; Ingelsson E; Weissman IL; Leeper NJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15818-15826. PubMed ID: 32541024
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of efferocytosis in atherosclerosis.
Shu LX; Cao LL; Guo X; Wang ZB; Wang SZ
J Mol Med (Berl); 2024 Jul; 102(7):831-840. PubMed ID: 38727748
[TBL] [Abstract][Full Text] [Related]
4. Sonodynamic Therapy Promotes Efferocytosis via CD47 Down-Regulation in Advanced Atherosclerotic Plaque.
Cao Y; Yao J; Gao W; Cao Z; Diabakte K; Wang L; Sun X; Tian Y
Int Heart J; 2022 Jan; 63(1):131-140. PubMed ID: 35034916
[TBL] [Abstract][Full Text] [Related]
5. Efferocytosis in atherosclerotic lesions: Malfunctioning regulatory pathways and control mechanisms.
Tajbakhsh A; Rezaee M; Kovanen PT; Sahebkar A
Pharmacol Ther; 2018 Aug; 188():12-25. PubMed ID: 29444453
[TBL] [Abstract][Full Text] [Related]
6. The Role of Efferocytosis in Atherosclerosis.
Kojima Y; Weissman IL; Leeper NJ
Circulation; 2017 Jan; 135(5):476-489. PubMed ID: 28137963
[TBL] [Abstract][Full Text] [Related]
7. The walking dead: macrophage inflammation and death in atherosclerosis.
Kavurma MM; Rayner KJ; Karunakaran D
Curr Opin Lipidol; 2017 Apr; 28(2):91-98. PubMed ID: 28134664
[TBL] [Abstract][Full Text] [Related]
8. The Impaired Mechanism and Facilitated Therapies of Efferocytosis in Atherosclerosis.
Wang Z; Su J; Gong F; Xue L; Su Z
J Cardiovasc Pharmacol; 2022 Sep; 80(3):407-416. PubMed ID: 35853202
[TBL] [Abstract][Full Text] [Related]
9. Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2
Wang W; Liu W; Fidler T; Wang Y; Tang Y; Woods B; Welch C; Cai B; Silvestre-Roig C; Ai D; Yang YG; Hidalgo A; Soehnlein O; Tabas I; Levine RL; Tall AR; Wang N
Circ Res; 2018 Nov; 123(11):e35-e47. PubMed ID: 30571460
[TBL] [Abstract][Full Text] [Related]
10. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.
Kojima Y; Volkmer JP; McKenna K; Civelek M; Lusis AJ; Miller CL; Direnzo D; Nanda V; Ye J; Connolly AJ; Schadt EE; Quertermous T; Betancur P; Maegdefessel L; Matic LP; Hedin U; Weissman IL; Leeper NJ
Nature; 2016 Aug; 536(7614):86-90. PubMed ID: 27437576
[TBL] [Abstract][Full Text] [Related]
11. Is CD47 a potentially promising therapeutic target in cardiovascular diseases? - Role of CD47 in cardiovascular diseases.
Cheng Q; Gu J; Adhikari BK; Sun L; Sun J
Life Sci; 2020 Apr; 247():117426. PubMed ID: 32061866
[TBL] [Abstract][Full Text] [Related]
12. Enhancing CAR Macrophage Efferocytosis Via Surface Engineered Lipid Nanoparticles Targeting LXR Signaling.
Chuang ST; Stein JB; Nevins S; Kilic Bektas C; Choi HK; Ko WK; Jang H; Ha J; Lee KB
Adv Mater; 2024 May; 36(19):e2308377. PubMed ID: 38353580
[TBL] [Abstract][Full Text] [Related]
13. Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis.
Flores AM; Hosseini-Nassab N; Jarr KU; Ye J; Zhu X; Wirka R; Koh AL; Tsantilas P; Wang Y; Nanda V; Kojima Y; Zeng Y; Lotfi M; Sinclair R; Weissman IL; Ingelsson E; Smith BR; Leeper NJ
Nat Nanotechnol; 2020 Feb; 15(2):154-161. PubMed ID: 31988506
[TBL] [Abstract][Full Text] [Related]
14. Macrophage SR-B1 in atherosclerotic cardiovascular disease.
Huby T; Le Goff W
Curr Opin Lipidol; 2022 Jun; 33(3):167-174. PubMed ID: 35258032
[TBL] [Abstract][Full Text] [Related]
15. Platelet Membrane-Coated Nanocarriers Targeting Plaques to Deliver Anti-CD47 Antibody for Atherosclerotic Therapy.
Chen L; Zhou Z; Hu C; Maitz MF; Yang L; Luo R; Wang Y
Research (Wash D C); 2022; 2022():9845459. PubMed ID: 35118420
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of failed apoptotic cell clearance by phagocyte subsets in cardiovascular disease.
Thorp EB
Apoptosis; 2010 Sep; 15(9):1124-36. PubMed ID: 20552278
[TBL] [Abstract][Full Text] [Related]
17. LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation.
Ye ZM; Yang S; Xia YP; Hu RT; Chen S; Li BW; Chen SL; Luo XY; Mao L; Li Y; Jin H; Qin C; Hu B
Cell Death Dis; 2019 Feb; 10(2):138. PubMed ID: 30755588
[TBL] [Abstract][Full Text] [Related]
18. Cyclophilin A Impairs Efferocytosis and Accelerates Atherosclerosis by Overexpressing CD 47 and Down-Regulating Calreticulin.
Anandan V; Thulaseedharan T; Suresh Kumar A; Chandran Latha K; Revikumar A; Mullasari A; Kartha CC; Jaleel A; Ramachandran S
Cells; 2021 Dec; 10(12):. PubMed ID: 34944106
[TBL] [Abstract][Full Text] [Related]
19. Advances in Anti-metabolic Disease Treatments Targeting CD47.
Gao L; He Z; Wu Y
Curr Pharm Des; 2022; 28(46):3720-3728. PubMed ID: 36201266
[TBL] [Abstract][Full Text] [Related]
20. Efferocytosis and Atherosclerosis: Regulation of Phagocyte Function by MicroRNAs.
Tajbakhsh A; Bianconi V; Pirro M; Gheibi Hayat SM; Johnston TP; Sahebkar A
Trends Endocrinol Metab; 2019 Sep; 30(9):672-683. PubMed ID: 31383556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
